Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns

NCT00886470 is registered in ClinicalTrials.gov with Noveome Biotherapeutics, formerly Stemnion as lead sponsor.

NCT NCT00886470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00886470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2009
Completion date
March 31, 2010
Enrollment
16 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

burns